Sign In
Buy SNY
$43.98
-0.680 (-1.52%)
At Close: Jul 20, 2026
Sanofi reports encouraging early results for COVID-19 mRNA vaccine candidate
02:34am, Tuesday, 28'th Sep 2021
Sanofi said Tuesday that it recorded positive interim results from an early study into its first mRNA-based Covid-19 vaccine candidate.
Analyst Upgrades Sanofi On COVID-19 Vaccine Optimism
12:01pm, Monday, 27'th Sep 2021
Sanofi SA (NASDAQ:SNY) shares traded higher by 0.4% on Monday after the company scored an analyst upgrade. The Analyst: SVB Leerink analyst Geoffrey Porges upgraded Sanofi from Market Perform to Outpe
5 European Dividend Aristocrats Offer Huge Income and Growth Potential
07:27am, Monday, 27'th Sep 2021
With September and the third quarter almost over, many investors are looking to the fourth quarter and beyond.
Sanofi: Availability of the Q3 2021 Memorandum for modelling purposes
01:30am, Friday, 24'th Sep 2021
Availability of the Q 3 202 1 Memorandum for modelling purposes
Sanofi, Regeneron, Share Competitive Libtayo Survival Data in 1L NSCLC
06:45am, Monday, 20'th Sep 2021
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) hope to expand Libtayo into a broader population with a chemo combo regimen. According to data released at the European So
5 COVID Vaccine Stocks With Late-Stage Candidates You'll Want to Watch
07:03am, Saturday, 18'th Sep 2021
Their vaccines could be late to the party. But the stocks might still be big winners.
AbbVie's Pain Is Sanofi's and Regeneron's Gain
05:57am, Saturday, 18'th Sep 2021
There are both winners and losers with the new Food and Drug Administration restrictions on JAK inhibitors.
How a Covid Vaccine Could Lift Sanofi's Stock
04:30am, Friday, 17'th Sep 2021
Sanofi's Covid vaccine is now in its Phase 3 trial, and the pharmaceutical company says results could come by the end of the year.
Glaxo, Pfizer, J&J and Sanofi Expected to Grab Biggest Shares of RSV Vaccine Business
02:22pm, Thursday, 09'th Sep 2021
GlaxoSmithKline PLC ( GSK , Financial) is forecasted to carve out more than 25% of a vaccine market that is expected to reach $10.5 billion by 2030. FiercePharma repotrted three other members of big p
Sanofi (SNY) Skin Disorder Drug Misses Goal in Phase III Study
12:38pm, Thursday, 09'th Sep 2021
Sanofi's (SNY) rilzabrutinib fails to meet the primary endpoint in a phase III study. It was added to its portfolio following the acquisition of Principia Biopharma last year.
Sanofi's BTK Inhibitor Disappoints In Phase 3 Autoimmune Disease Trial
10:04am, Thursday, 09'th Sep 2021
Sanofi SA's (NASDAQ: SNY) BTK inhibitor, rilzabrutinib, has flunked its first major clinical test. Rilzabrutinib was Principia Biopharma Inc's one of the key candidates that Sanofi acquired last ye
The 13 Ideally Priced Most Reliable Dividends On Earth For September
11:52pm, Wednesday, 08'th Sep 2021
The 13 Ideally Priced Most Reliable Dividends On Earth For September
Sanofi (SNY) to Buy Kadmon for $1.9B, Add cGVHD Drug Rezurock
11:00am, Wednesday, 08'th Sep 2021
Sanofi (SNY) offers $1.9 billion to buy Kadmon Holdings to strengthen its transplant business.
Kadmon Stock Soars as Sanofi Buys U.S. Biotech for $1.9 Billion
07:54am, Wednesday, 08'th Sep 2021
French drugmaker Sanofi is buying Kadmon, the U.S. biopharmaceutical company, for a total equity value of $1.9 billion.
Sanofi's $1.9 Billion Bet On Kadmon: What You Need to Know
06:30am, Wednesday, 08'th Sep 2021
Underlining the focus on inorganic growth, French pharma giant Sanofi (NASDAQ: SNY) announced a big-ticket acquisition just a month after another billion-dollar deal. Sanofi-Kadmon Deal Terms: Sano
